Carlsmed, Inc. - Common Stock (CARL)

Revenue jumped 65% as operating leverage turned positive in the quarter.

Carlsmed (NASDAQ:CARL) raised its full-year revenue outlook after third-quarter sales climbed 65%, as more surgeons adopted its personalized spine surgery products and procedure volume increased. The company reported revenue of $21.6 million for the quarter, up from $13.1 million a year earlier. Pr

Carlsmed (NASDAQ:CARL) outlined its strategy for expanding its personalized spine-surgery platform, citing clinical data, reimbursement changes and a planned cervical product launch as potential drivers of growth during a Bank of America small- and mid-cap virtual event. Chief Executive Officer Mik

Carlsmed (NASDAQ:CARL) reported second-quarter 2026 revenue of $18.9 million, up 57% from $12.1 million a year earlier, as growth in its aprevo lumbar platform and contributions from its newer cervical offering lifted procedure volumes. Chairman and Chief Executive Officer Mike Cordonnier said the

Carlsmed (CARL) Q1 2026 Earnings Transcript

Carlsmed (NASDAQ: CARL) stock rises on news of first personalized cervical plating procedure with its corra system.

Carlsmed (CARL) reported strong Q3 2025 results, beating revenue and EPS estimates with 98% YoY growth. The AI spine surgery firm also raised its full-year revenue guidance.